Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,458.00
Bid: 12,454.00
Ask: 12,458.00
Change: 66.00 (0.53%)
Spread: 4.00 (0.032%)
Open: 12,468.00
High: 12,492.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET COMMENT: Stocks Pointed Up Before UK, US, Eurozone Data

Fri, 17th Apr 2015 06:36

LONDON (Alliance News) - UK stocks are pointed to a higher open Friday, ahead of UK unemployment data and inflation numbers from the eurozone and the US.

IG says futures indicate the FTSE 100 to open 10 points higher at 7,070.0. The index closed down 0.5% at 7,060.45 on Thursday after hitting a new intraday record high of 7,119.35 in the first minute of trade.

On Wall Street Thursday, the DJIA ended slightly lower, the S&P 500 closed down 0.1%, and the Nasdaq Composite also ended down 0.1%.

In Asia Friday, the Japanese Nikkei closed down 1.2%, while the Hang Seng is up 0.3% and the Shanghai Composite is up 2.4%.

Japan's consumer confidence improved for the fourth straight month in March, surpassing expectations, survey data from the Cabinet Office showed. The consumer confidence index rose to 41.7 in March from 40.9 in the previous month. Economists had expected the index to increase to 41.3. The latest reading was the highest since December 2013, when it marked the same 41.7.

Investor focus will remain on Greece, after the International Monetary Fund ruled out allowing the cash-strapped country to delay scheduled debt repayments, while the European Commission voiced dissatisfaction over talks with Athens to solve Greek financial woes.

IMF chief Christine Lagarde said that a delay in Greek payments would constitute "additional financing" to Athens. A delay would be "clearly not a course of action that would...be recommendable" to the IMF's board, she said. "We have never had an advanced economy ask for payment delays," Lagarde said.

"If Greece does default on its payments and misses next Friday's deadline for reforms then that does not necessarily mean that it will leave the eurozone. The EU have told Greece that they will lend to them if they can also find another creditor. However with Greece's track record and its refusal to undertake any more plans in terms of austerity they may find it incredibly difficult to find any support," says James Hughes, chief market analyst at eToro.

AstraZeneca said on Friday the US Food and Drug Administration has granted orphan drug designation for its selumetinib treatment for uveal melanoma. The Orphan Drug Designation programme provides orphan status to drugs and biologics, which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US, it added.

FTSE 250-listed outsourcer Serco Group said it has received 94.7% acceptances for its one-for-one rights issue launched last month after the group posted a huge loss on the back of massive provisions taken on onerous contracts.

Serco said in March it would launch the GBP555 million rights issue in order to refinance its existing lending facilities and cut its gross debt pile by GBP450 million. The rights issue emerged after it posted a pretax loss for 2014 of GBP1.35 billion, having booked GBP1.31 billion in impairment charges and writedowns related to problem contracts.

The UK Competition and Markets Authority said there has been no material change in circumstances or any special reason for it reverse its ruling to force Ryanair Holdings to sell down its stake in Irish flag carrier Aer Lingus Group. Ryanair requested in February that the CMA, the UK's competition authority, re-examine its decision to require Ryanair to sell down its 29.8% stake in Aer Lingus to 5%.

In the economic calendar, UK unemployment and wage data is at 0930 BST before eurozone consumer prices at 1000 BST and US CPI at 1330 BST. After the close of London stock markets, there is the US Reuters/Michigan consumer sentiment index at 1900 BST.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.